These observations confirmed that ZFP14 served as both a novel target for METTL14‐mediated m6A modification and a significant tumour suppressor in ccRCC, shedding light on the cellular and molecular operations in ccRCC and opening up possibilities for novel therapeutic strategies. This evidence concerns the gene ZFP14 and nonpapillary renal cell carcinoma.